Hologic (HOLX)
(Delayed Data from NSDQ)
$80.24 USD
+1.02 (1.29%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $80.25 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$80.24 USD
+1.02 (1.29%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $80.25 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
Zacks News
Hologic (HOLX) Divests Cynosure to Focus on Women's Health
by Zacks Equity Research
Hologic (HOLX) expects to witness favorable outcomes from the sell-off of the Cynosure medical aesthetics business, which was its loss-making arm since 2017.
Hologic (HOLX) Up 13.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hologic (HOLX) to Showcase Health Solutions Portfolio at RSNA
by Zacks Equity Research
Hologic (HOLX) to highlight its latest offerings in its breast health portfolio at the ongoing annual RSNA meet.
Hologic's LOCalizer RFID Tag in Breast Health Gets CE Mark
by Zacks Equity Research
Hologic (HOLX) wins the CE Mark for long-term use of LOCalizer RFID tag, providing more flexibility to breast-conserving surgery.
Hologic (HOLX) Set to Divest Medical Aesthetics Business
by Zacks Equity Research
Hologic (HOLX) to sell off its medical aesthetics business to focus on other core segments.
Hologic's (HOLX) 3DQuorum Imaging Technology Gets FDA Nod
by Zacks Equity Research
The regulatory clearance is likely to boost Hologic's (HOLX) Breast and Skeletal Health Solutions business segment.
Hologic's Aptima Genitalium Assay Gets Clinically Verified
by Zacks Equity Research
This study result is expected to be a major stride forward in Hologic's (HOLX) commitment toward strengthening its Diagnostic Solutions business.
Hologic's (HOLX) Q4 Earnings Meet, Revenues Top Estimates
by Zacks Equity Research
Hologic (HOLX) exhibits robust fourth-quarter growth fueled by strong segmental performance.
Hologic (HOLX) Q4 Earnings Match Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 0.00% and 2.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Can Segmental Growth Aid Hologic (HOLX) in Q4 Earnings?
by Zacks Equity Research
Developments in Breast Health and Molecular Diagnostics businesses are likely to have aided Hologic's (HOLX) performance in fourth-quarter fiscal 2019.
Impressive Near-Term Outlook for Medical Instruments Industry
by Urmimala Biswas
Growing medical awareness and economic prosperity enhance the uptake of medical instruments in the emerging economies.
Hologic (HOLX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Hologic (HOLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Invest in Hologic (HOLX) Stock Now
by Zacks Equity Research
Hologic (HOLX) is generating consistently positive results, thanks to impressive developments.
DexCom (DXCM) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Hologic (HOLX) Beats on Q3 Earnings, Ups '19 Revenue View
by Zacks Equity Research
Hologic's (HOLX) strong top-line growth in Q3 is led by a solid year-over-year rise in core businesses like Breast Health and Molecular Diagnostics.
Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More
by Zacks Equity Research
Solid growth in emerging markets is expected to be an added positive this earnings season.
Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Illumina's (ILMN) witnessed top-line growth across its high and low throughput categories in the second quarter of 2019.
GNC Holdings (GNC) Q2 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
GNC Holdings' (GNC) Q2 revenues decline year over year at each of the three operating segments.
Zimmer Biomet (ZBH) Beats on Q2 Earnings, Narrows '19 View
by Zacks Equity Research
Zimmer Biomet (ZBH) observes strength in the Asia Pacific and EMEA regions as well as in the S.E.T. business.
Omnicell (OMCL) Beats on Earnings in Q2, Tapers '19 EPS View
by Zacks Equity Research
Omnicell (OMCL) aims at product innovation through R&D.
Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Higher revenues, solid segmental performance and strong organic growth across businesses benefit Stryker's (SYK) Q2 earnings.
Merit Medical (MMSI) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Higher revenues and solid segmental performance margins benefit Merit Medical's (MMSI) Q2 earnings. However, contraction in both gross and operating margins remains a concern.
Chemed (CHE) Earnings Top Estimates in Q2, Margins Expand
by Zacks Equity Research
It is encouraging to note that Chemed (CHE) witnessed solid revenue growth across both of its key subsidiaries.
ResMed's (RMD) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed (RMD) achieves double-digit global revenue growth in the fourth quarter, led by strong sales at Software-as-a-Service businesses as well as of new mask products and devices.
LabCorp's (LH) Q2 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
While rising acquisitions and a favorable mix contribute to LabCorp's (LH) Diagnostics business, the disposition of certain businesses and the implementation of PAMA dented the company's growth in Q2.